Acrylic Acid And Derivatives Patents (Class 424/487)
-
Patent number: 8349354Abstract: The present invention is directed to a hemostatic composite structure having a bioabsorbable fabric or non-woven substrate having at least two major oppositely facing surface areas and a continuous non-porous polymer-based film that is laminated on one major surface of said substrate. The bioabsorbable fabric substrate can be an oxidized polysaccharide and/or the non-woven substrate can be made from bioabsorbable, non-cellulosic derived polymers. The continuous non-porous polymer based film can be a bioabsorbable polymer. The present invention also relates to a method for providing hemostasis by applying a composite structure described herein onto a wound site in need of a hemostatic device wherein a major surface of the substrate without the film layer is applied onto the wound site.Type: GrantFiled: September 22, 2009Date of Patent: January 8, 2013Assignee: Ethicon, Inc.Inventor: Sasa Andjelic
-
Patent number: 8344042Abstract: The invention provides for a biodegradable synthetic bone composition comprising a biodegradable hydrogel polymer scaffold comprising a plurality of hydrolytically unstable linkages, and an inorganic component; such as a biodegradable poly(hydroxyethylmethacrylate)/hydroxyapatite (pHEMA/HA) hydrogel composite possessing mineral content approximately that of human bone.Type: GrantFiled: December 8, 2009Date of Patent: January 1, 2013Assignee: The Regents of the University of CaliforniaInventors: Gao Liu, Dacheng Zhao, Eduardo Saiz, Antoni P. Tomsia
-
Patent number: 8337890Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.Type: GrantFiled: March 12, 2010Date of Patent: December 25, 2012Assignee: Tris Pharma IncInventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8323693Abstract: There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.Type: GrantFiled: March 12, 2003Date of Patent: December 4, 2012Assignees: Medrx Co., Ltd., Nippon Shinyaku Co., Ltd.Inventors: Hidetoshi Hamamoto, Keiko Yamasaki, Hideakira Yokoyama, Akihiko Hirata, Takeru Fujii
-
Patent number: 8314195Abstract: Biologically compatible polymers carry at least two different kinds of functional groups. Adhesive formulations include a biologically compatible adhesive, which can be used with a bridging molecule.Type: GrantFiled: January 23, 2009Date of Patent: November 20, 2012Assignee: The Johns Hopkins UniversityInventor: Jennifer H. Elisseeff
-
Publication number: 20120288566Abstract: The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity.Type: ApplicationFiled: October 5, 2010Publication date: November 15, 2012Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Michael Friedman, Doron Steinberg, Irith Gati
-
Patent number: 8299178Abstract: A novel class of mixed micelles formed with critical micelle concentration (Cmc) character's diblock copolymer, and temperature-sensitive character's diblock copolymer were disclosed. The mixed micelles possess complementary effects in adjusting external temperature shift (storage vs. body temperature) and concentration change (dilution after intravenous injection). The mixed micelles of the present invention can serve as a potential injectable drug delivery system for anticancer drugs, such as doxorubicin and many others.Type: GrantFiled: March 25, 2009Date of Patent: October 30, 2012Assignee: National Tsing Hua UniversityInventors: Ging-Ho Hsiue, Chun-Liang Lo, Sheng-Jie Lin, Hsieh-Chih Tsai
-
Publication number: 20120263792Abstract: Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing lull access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.Type: ApplicationFiled: June 22, 2012Publication date: October 18, 2012Applicant: DEPOMED, INC.Inventors: JONG LIM, John N. Shell, Jenny Louie-Helm
-
Patent number: 8273828Abstract: Biocompatible polymers having polymer backbones with at least one secondary amine suitable for diazeniumdiolation are disclosed. Specifically, methods for providing secondary amines-containing polymers using epoxide-opening reactions are provided. More specifically, nitric oxide-releasing medical devices made using these polymers are disclosed.Type: GrantFiled: July 24, 2007Date of Patent: September 25, 2012Assignee: Medtronic Vascular, Inc.Inventors: Mingfei Chen, Peiwen Cheng, Kishore Udipi
-
Publication number: 20120231075Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.Type: ApplicationFiled: May 17, 2012Publication date: September 13, 2012Applicant: Endo Pharmaceuticals Inc.Inventors: Huai-Hung Kao, Yadi Zeng, Michelle Howard-Sparks, Fai Jim
-
Patent number: 8246993Abstract: New hydrogel, including a hydrogel containing cationic BSA is included in a vaccine to stimulate the immune system to increase the potency of the vaccine.Type: GrantFiled: June 9, 2005Date of Patent: August 21, 2012Assignee: Cytogel Pharma, LLCInventors: Daqing Wu, Chih-Chang Chu, Joseph Carozza
-
Patent number: 8246994Abstract: New hydrogel, including a hydrogel containing cationic BSA is included in a vaccine to stimulate the immune system to increase the potency of the vaccine.Type: GrantFiled: May 30, 2008Date of Patent: August 21, 2012Assignee: Cytogel Pharma, LLCInventors: Daqing Wu, Chih-Chang Chu, Joseph Carozza
-
Publication number: 20120201891Abstract: A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier.Type: ApplicationFiled: March 30, 2011Publication date: August 9, 2012Inventors: Jeremy Cottrell, Giacinto Gaetano, Mahmoud El-Tamimy, Nicholas Kennedy, Paul David Gavin
-
Patent number: 8236351Abstract: Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.Type: GrantFiled: October 21, 2010Date of Patent: August 7, 2012Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox
-
Patent number: 8236851Abstract: The provision of animal feed pellets is described, which pellets comprise, as antibiotic, a pleuromutilin derivative is stabilized form, namely in the form of microspherules. The pleuromutilin derivatives in question have the general formula (I) wherein R1 is ethyl or vinyl, there is either a double bond or a single bond between carbon atoms 1 and 2, Ra and Rb are each independently of the other hydrogen or halogen, and T is a short or long-chain organic radical.Type: GrantFiled: November 27, 2002Date of Patent: August 7, 2012Assignee: Novartis AGInventors: Susanne Christine Wieland-Berghausen, Ferenc Jozsef Rakoczi, Brigitte Monika Cron-Eckhardt
-
Patent number: 8236328Abstract: A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.Type: GrantFiled: July 8, 2008Date of Patent: August 7, 2012Assignee: Bend Research, Inc.Inventors: Walter C. Babcock, William J. Curatolo, Dwayne T. Friesen, Rodney J. Ketner, Julian B. Lo, James A. S. Nightingale, Ravi M. Shanker, James B. West
-
Patent number: 8231906Abstract: Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.Type: GrantFiled: July 10, 2008Date of Patent: July 31, 2012Assignee: Noven Pharmaceuticals, Inc.Inventor: Juan Mantelle
-
Patent number: 8231929Abstract: Methods for coating medical devices for implantation within a body vessel are provided comprising providing a cylindrical container, placing a medical device inside the cylindrical container, and applying a polymer in liquid form inside the container.Type: GrantFiled: October 23, 2007Date of Patent: July 31, 2012Assignee: Cook Medical Technologies LLCInventor: Jichao Sun
-
Publication number: 20120189698Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: ApplicationFiled: January 23, 2012Publication date: July 26, 2012Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Iván LÓPEZ-BELMONTE ENCINA, Ibon GUTIERRO ADURIZ, Philippe MAINCENT
-
Publication number: 20120177735Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.Type: ApplicationFiled: September 29, 2010Publication date: July 12, 2012Applicant: Center Laboratories, Inc.Inventors: Huai-Cheng Lee, Chien-Fen Chen, Chuen-Lin Din, Rong Jin Lin
-
Patent number: 8206738Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.Type: GrantFiled: September 12, 2003Date of Patent: June 26, 2012Assignees: Corium International, Inc., A.V. Topchiev Institute of Petrochemical SynthesisInventors: Parminder Singh, Adrian Faasse, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir R. Bairamov
-
Patent number: 8202548Abstract: A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid composition. A method of delivering chlorine dioxide includes providing a gel or solid composition as described and degelling the gel or dissolving the solid composition to dispense the chlorine dioxide therefrom. A method of disinfecting a target such as water, wastewater, or a surface comprises delivering chlorine dioxide as above and permitting the polymer to precipitate out of the mixture. Aqueous chlorine dioxide is then recovered and applied to the target.Type: GrantFiled: July 19, 2007Date of Patent: June 19, 2012Assignee: Dharma IP, LLCInventors: Sunggyu Lee, Patricia Roberts
-
Patent number: 8202540Abstract: The invention relates to superfine microparticles and nanoparticles and a process for their gentle preparation with exclusion of water or minimization of water and/or exclusion of plasticizers and/or reduced temperature load, in which a matrix material is subjected to a high-pressure homogenization process in an anhydrous or water-poor medium and/or at low temperatures, preferably room temperature (20° C.) and in particular below the freezing point of water, which leads to a gentle particle reduction with minimization of the impairment of the chemical stability of the homogenized material.Type: GrantFiled: July 10, 2000Date of Patent: June 19, 2012Assignee: Abbott GmbH & Co., KGInventors: Rainer H. Müller, Karsten Krause, Karsten Mäder
-
Publication number: 20120150096Abstract: Implantable or insertable medical devices are provided, which comprises: (a) a biocompatible polymer; and (b) at least one therapeutic agent selected from an anti-inflammatory agent, an analgesic agent, an anesthetic agent, and an antispasmodic agent. The medical devices are adapted for implantation or insertion at a site associated with pain or discomfort upon implantation or insertion. In many embodiments, the therapeutic will be selected from at least one of (i) ketorolac and pharmaceutically acceptable salts thereof (e.g., ketorolac tromethamine) and (ii) 4-diethylamino-2-butynylphenylcyclohexyl glycolate and pharmaceutically acceptable salts thereof (e.g., oxybutynin chloride). Also provided are uses for the implantable or insertable medical devices, which uses comprise reducing pain or discomfort accompanying the implantation or insertion of such devices. Further uses may comprise reducing microbial buildup along the device.Type: ApplicationFiled: February 24, 2012Publication date: June 14, 2012Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Jianmin LI, Danielle Conley, Weenna Bucay-Couto, Cang Duy Dao, Hamid Davoudi, Raymond J. Lareau, Kathleen M Miller
-
Patent number: 8177950Abstract: Disclosed are thermoresponsive microparticle composite hydrogels comprising poly(N-isopropyl acrylamide) and polyacrylamide, and methods regarding their manufacture and their use. The present invention provides in one aspect a thermoresponsive microparticle hydrogel, wherein the matrix morphology is controllably and selectively altered by incorporation of thermoresponsive nano/micro-particles. The particles are preferably poly(N-isopropyl acrylamide) particles. The present invention also provides methods of making and using such hydrogels.Type: GrantFiled: November 21, 2008Date of Patent: May 15, 2012Assignee: Tennessee Technological UniversityInventors: Jeffery W. Thompson, Holly Stretz, Pedro E. Arce
-
Publication number: 20120107394Abstract: An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel, exposing the gel to an aqueous solution comprising a first polyelectrolyte to form a polyelectrolyte-coated hydrogel, exposing the polyelectrolyte-coated hydrogel to a second polyelectrolyte to form a crosslinked matrix and exposing the matrix to conditions which eliminates, or at least reduces, protein binding sites on the matrix.Type: ApplicationFiled: June 2, 2010Publication date: May 3, 2012Inventors: Harald Stover, Nicholas Burke, Casey Mills
-
Publication number: 20120100217Abstract: Disclosed herein is a polymeric material comprising a conductive polymer substantially homogeneously distributed within a hydrogel. Also disclosed are methods for making the polymeric material and uses for the polymeric material.Type: ApplicationFiled: June 9, 2011Publication date: April 26, 2012Applicant: NEWSOUTH INNOVATIONS PTY LIMITEDInventors: Rylie Adelle GREEN, Laura Anne POOLE-WARREN, Sungchul BAEK, Penny Jo MARTENS
-
Patent number: 8147898Abstract: A drug coating is formed by vaporizing a drug in a deposition chamber having an implantable medical device such as a stent loaded therein. A vacuum is utilized to lower the pressure within the deposition chamber, thereby reducing the temperature necessary to vaporize the drug. The drug is then deposited onto the implantable medical device while in a vapor phase to form the drug coating.Type: GrantFiled: July 25, 2008Date of Patent: April 3, 2012Assignee: Medtronic Vascular, Inc.Inventors: Paul Coates, Brian Cook
-
Patent number: 8143042Abstract: The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers.Type: GrantFiled: January 12, 2007Date of Patent: March 27, 2012Assignee: Massachusetts Institute of TechnologyInventors: Christopher J. Bettinger, Joost P. Bruggeman, Lino Da Silva Ferreira, Jeffrey M. Karp, Robert S. Langer, Christiaan Nijst, Andreas Zumbuehl, Jason Burdick, Sonia J. Kim
-
Publication number: 20120064164Abstract: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.Type: ApplicationFiled: May 20, 2010Publication date: March 15, 2012Applicant: INVENTIA HEALTHCARE PRIVATE LIMITEDInventors: Sunil Beharilal Jaiswal, Vaibhavi Ankur Shah, Sunil Deviprasad Tiwari
-
Publication number: 20120064142Abstract: This invention relates to a polymeric pharmaceutical dosage form for the delivery, in use, of at least one pharmaceutical composition in a rate-modulated and site-specific manner. The dosage form comprises a biodegradable, polymeric, scaffold incorporating loaded with at least one active pharmaceutical ingredient (API). The polymer or polymers making up the scaffold degrade in a human or animal body in response to or in the absence of specific biological stimuli and, on degradation, release the API or APIs in an area where said stimuli are encountered. Preferably the polymeric scaffold is formed from poly (D1L-lactide) (PLA) and polymethacrylate (Eudragit S100/ES100) polymers.Type: ApplicationFiled: November 30, 2009Publication date: March 15, 2012Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Viness Pillay, Yahya Essop Choonara, Bongani Sibeko, Sheri-Lee Harilall, Samatha Pillay, Girish Modi, Sunny Esayegbemu Iyuke, Dinesh Naidoo
-
Patent number: 8133511Abstract: Matrix controlled diffusion drug delivery systems are described herein which are based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.Type: GrantFiled: July 8, 2009Date of Patent: March 13, 2012Assignee: Bausch & Lomb IncorporatedInventors: Jay F. Kunzler, Derek Schorzman, Daniel M. Ammon, Jr.
-
Patent number: 8133512Abstract: Matrix controlled diffusion drug delivery systems based on one or more silicon-containing monomers of the general formula: wherein L, X?, n, R1, R2, R3, R4, R5, R6, R7 and V are as set forth herein.Type: GrantFiled: July 8, 2009Date of Patent: March 13, 2012Assignee: Bausch & Lomb IncorporatedInventors: Jay F. Kunzler, Derek Schorzman, Daniel M. Ammon, Jr.
-
Patent number: 8133510Abstract: The invention relates to a film-shaped form of administration for topically administering at least one agent and/or nutrient to a living being. Said form of administration comprises at least one agent-containing and/or nutrient-containing layer that is based on crosslinked hydrophilic polymers which are crosslinked with at least one polyacrylic acid derivative.Type: GrantFiled: December 13, 2004Date of Patent: March 13, 2012Assignee: LTS Lohmann Therapie-Systeme AGInventors: Johannes Bartholomaeus, Maria Cristina Vázquez Lantes
-
Publication number: 20120040002Abstract: Biocompatible and resorbable melt derived glass compositions which include: SiO2 60-70 weight-%, Na2O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P2O5 0.5-3.0 weight-%, B2O3 0-15 weight-%, Al2O3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibres manufactured from these glass compositions, medical devices containing fibres of the invention, the use of these compositions for the manufacture of glass fibre and the use of the fibres for the manufacture of medical devices are also disclosed.Type: ApplicationFiled: April 20, 2010Publication date: February 16, 2012Inventors: Timo Lehtonen, Jukka Tuominen, Fredrik Ollila
-
Publication number: 20120021053Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.Type: ApplicationFiled: September 30, 2011Publication date: January 26, 2012Applicant: COSMO TECHNOLOGIES LIMITEDInventors: Roberto VILLA, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
-
Publication number: 20120015034Abstract: The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly poly (hydroxyalkyl(meth) acrylamide mono/di-lactate interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention comprise monomers, which have modifiable functionality. The functionality of the monomers can for example be modified by the presence of hydrolysable groups. The modification is effected by the incubation, leading to a change of the water solubility characteristics of the polymer. The polymers used in the present invention contain hydrolysable chemical groups. As a result the polymer's solution characteristics, specifically its lower critical solution temperature (LCST), change upon incubation.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: Universiteit UtrechtInventors: Wilhelmus Everhardus HENNINK, Cornelis Franciscus Van Nostrum, Marinus Jacob Van Steenbergen, Osamu Soga, Cristianne Johanna Derdinand Rijcken
-
Patent number: 8097277Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.Type: GrantFiled: November 19, 2010Date of Patent: January 17, 2012Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Adam D. Miller
-
Publication number: 20120003316Abstract: This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations.Type: ApplicationFiled: June 3, 2009Publication date: January 5, 2012Inventors: Deshika Reddy, Oluwatoyin Ayotomilola Adeleke, Viness Pillay, Yahya Choonara
-
Patent number: 8088417Abstract: A method of making a composition having the property of being able to store chlorine dioxide includes mixing an aqueous chlorine dioxide solution with a superabsorbent, water-soluble polymer that is substantially unreactive with chlorine dioxide and permitting a mixture formed thereby to form one of a gel and a solid composition. A method of delivering chlorine dioxide includes providing a gel or solid composition as described and degelling the gel or dissolving the solid composition to dispense the chlorine dioxide therefrom. A method of disinfecting a target such as water, wastewater, or a surface comprises delivering chlorine dioxide as above and permitting the polymer to precipitate out of the mixture. Aqueous chlorine dioxide is then recovered and applied to the target.Type: GrantFiled: May 15, 2007Date of Patent: January 3, 2012Assignee: Dharma IP, LLCInventors: Sunggyu Lee, Patricia Roberts
-
Publication number: 20110318413Abstract: The present invention relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof and one or more release controlling hydrophobic materials optionally coated with combination of one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials; wherein said formulation provides controlled release of the darifenacin over the period of 24 hours. The present invention further relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof, wherein darifenacin is incorporated in a matrix comprising one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials.Type: ApplicationFiled: June 22, 2011Publication date: December 29, 2011Applicant: MICRO LABS LIMITEDInventors: Rajesh Kshirsagar, Ganesh Shinde, Pravin Kamble
-
Publication number: 20110300212Abstract: The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.Type: ApplicationFiled: July 25, 2011Publication date: December 8, 2011Inventors: Stephen Mark McAllister, Ronald K. Raby, JR., Adrian Brown, Allan J. Clarke, Daniel N. Margetson, Wayne Matthews
-
Publication number: 20110293721Abstract: This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in this instance, piroxicam.Type: ApplicationFiled: May 25, 2011Publication date: December 1, 2011Inventors: Changjin Wang, Eric Y. Sheu, Nancy Vuong
-
Patent number: 8066904Abstract: Inhalation of low levels of nitric oxide can rapidly and safely decrease pulmonary hypertension in mammals. Precise delivery of nitric oxide at therapeutic levels of 20 to 100 ppm and inhibition of reaction of nitric oxide with oxygen to form toxic impurities such as nitrogen dioxide can provide effective inhalation therapy for pulmonary hypertension.Type: GrantFiled: August 28, 2002Date of Patent: November 29, 2011Assignee: Geno LLCInventors: David H. Fine, Stephen J. MacDonald, David Rounbehler, David Wheeler, Jonathan L. Rolfe, George Jarvis
-
Publication number: 20110287078Abstract: The invention provides porous biomaterials and methods for forming porous biomaterials. The porous biomaterials of the invention comprise a biocompatible polymer scaffold defining an array of pores, wherein substantially all the pores have a similar diameter, wherein the mean diameter of the pores is between about 20 and about 90 micrometers, wherein substantially all the pores are each connected to at least 4 other pores, and wherein the diameter of substantially all the connections between the pores is between about 15% and about 40% of the mean diameter of the pores. The invention also provides implantable devices comprising a layer of a biomaterial, and methods for promoting angiogenesis in and around an implantable biomaterial.Type: ApplicationFiled: June 9, 2011Publication date: November 24, 2011Applicant: UNIVERSITY OF WASHINGTONInventors: Buddy D. Ratner, Andrew Marshall
-
Publication number: 20110287102Abstract: The present invention relates to chain extenders, processes for their preparation and their use in the preparation of biocompatible biodegradable polyurethanes and polyurethane ureas for biomedical applications such as stents, scaffolds for tissue engineering. The chain extenders comprise a compound of formula.Type: ApplicationFiled: June 20, 2011Publication date: November 24, 2011Applicant: Polynovo Biomaterials Pty LimitedInventors: Pathiraja Arachchillage Gunatillake, Timothy Graeme Moore, Raju Adhikari
-
Patent number: 8062667Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.Type: GrantFiled: March 15, 2007Date of Patent: November 22, 2011Assignee: Tris Pharma, Inc.Inventors: Ketan Mehta, Yu-Hsing Tu
-
Patent number: 8048450Abstract: An aqueous dispersion of hydrogel nanoparticles and methods of making the aqueous dispersion of hydrogel nanoparticles having an interpenetrating polymer network (“IPN”) are described. The uniformed sized mono-disperse IPN nanoparticles have inverse thermo gelation properties that allow therapeutic medications to be uniformly distributed in a liquid form of the aqueous dispersion of hydrogel nanoparticles. Such medications can then be released from a solid form of the aqueous dispersion of hydrogel nanoparticles in time dependant manor.Type: GrantFiled: December 9, 2004Date of Patent: November 1, 2011Assignee: University of North TexasInventors: Zhibing Hu, Xiaohu Xia
-
Publication number: 20110244045Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.Type: ApplicationFiled: May 11, 2009Publication date: October 6, 2011Applicant: TIARA PHARMACEUTICALS ,INC.Inventors: Yadon Arad, Liang C. Dong
-
Patent number: 8030262Abstract: Provided are methods of cleansing dyed hair comprising applying to dyed hair a composition comprising anionic surfactant and a hydrophobically-modified polymer capable of binding surfactant thereto.Type: GrantFiled: September 20, 2010Date of Patent: October 4, 2011Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Russel M. Walters, Anthony J. Cossa, Joseph J. Librizzi